Search by PDB author

Crystal structure of a truncated variant of the human p73 tetramerization domain
Descriptor:	TUMOR PROTEIN P73
Authors:	Joerger, A.C.
Deposit date:	2009-08-21
Release date:	2009-10-06
Last modified:	2019-05-08
Method:	X-RAY DIFFRACTION (2 Å)
Cite:	Structural Evolution of P53, P63, and P73: Implication for Heterotetramer Formation. Proc.Natl.Acad.Sci.USA, 106, 2009

Crystal structure of the human p73 tetramerization domain
Descriptor:	TUMOR PROTEIN P73
Authors:	Joerger, A.C.
Deposit date:	2009-08-21
Release date:	2009-10-06
Last modified:	2019-05-08
Method:	X-RAY DIFFRACTION (1.7 Å)
Cite:	Structural Evolution of P53, P63, and P73: Implication for Heterotetramer Formation. Proc.Natl.Acad.Sci.USA, 106, 2009

Structure of the human p73 tetramerization domain (crystal form II)
Descriptor:	TUMOR PROTEIN P73
Authors:	Joerger, A.C.
Deposit date:	2009-09-21
Release date:	2009-10-13
Last modified:	2023-12-20
Method:	X-RAY DIFFRACTION (2.3 Å)
Cite:	Structural Evolution of P53, P63, and P73: Implication for Heterotetramer Formation. Proc.Natl.Acad.Sci.USA, 106, 2009

Crystal Structure of Human Anaplastic Lymphoma Kinase in complex with 7-azaindole based inhibitor
Descriptor:	3-[1-(2,5-difluorobenzyl)-1H-pyrazol-4-yl]-5-(1-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridine, ALK tyrosine kinase receptor
Authors:	Hosahalli, S, Krishnamurthy, N.R, Lakshminarasimhan, A.
Deposit date:	2013-03-18
Release date:	2013-07-17
Last modified:	2023-11-08
Method:	X-RAY DIFFRACTION (2.7 Å)
Cite:	Discovery of 7-azaindole based anaplastic lymphoma kinase (ALK) inhibitors: wild type and mutant (L1196M) active compounds with unique binding mode Bioorg.Med.Chem.Lett., 23, 2013